• General Dermatology
  • Eczema
  • Chronic Hand Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Prurigo Nodularis
  • Buy-and-Bill

Article

Glaxo's Stiefel unit to promote Amgen's Enbrel in U.S.

London - The Stiefel unit of GlaxoSmithKline, based here, will promote Amgen’s Enbrel (etanercept) psoriasis treatment to U.S. dermatologists, Bloomberg News reports.

London

- The Stiefel unit of GlaxoSmithKline, based here, will promote Amgen’s Enbrel (etanercept) psoriasis treatment to U.S. dermatologists, Bloomberg News reports.

The partnership, according to a Glaxo statement, “has no impact” on another Amgen co-promotion agreement with Pfizer, which sells Enbrel outside the region and, with California-based Amgen, in North America. Enbrel is also approved to treat rheumatoid arthritis.

Glaxo agreed to buy Stiefel Laboratories, based in Coral Gables, Fla., for $2.9 billion in April 2009.

Related Videos
3 experts are featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
2 experts in this video
2 experts in this video
2 experts in this video
3 experts in this video
3 experts in this video
© 2024 MJH Life Sciences

All rights reserved.